Background Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine are now used in most countries. To monitor global and regional progress towards improving child health and to inform national policies for disease prevention and treatment, we prepared global, regional, and national disease burden estimates for these pathogens in children from 2000 to 2015.
Introduction
Streptococcus pneumoniae (pneumococcus) and Haemo philus influenzae type b (Hib) are common causes of pneumonia, meningitis, and other serious infections in children. Pneumococcus was estimated to be responsible for 735 000 deaths in HIV-uninfected children and 14·5 million total illnesses in children in 2000. 1 Hib was estimated to have caused 363 000 deaths in HIV-uninfected children and 8·1 million total episodes in children in the same year. 2 These estimates represent the most recent, publicly available WHO national-level disease burden measures for these pathogens. Updated regional mortality estimates were published by WHO for 2008, estimating 541 000 pneumococcal deaths and 203 000 Hib deaths that year. 3 Several important vaccine developments have occurred since 2000. Protein-polysaccharide conjugate Hib vac cines are now included in the routine immunisation schedule of almost every country worldwide. By the end of 2015, 129 countries, including 54 low-income and middle-income countries eligible for vaccine funding support from Gavi, the Vaccine Alliance, had introduced pneumococcal conjugate vaccine (PCV); this number increased to 141 countries by September, 2017. 4 Where Hib vaccine is used routinely with high coverage, virtual elimination of invasive Hib disease in children has occurred. [5] [6] [7] Similarly, PCV has substantially reduced vaccine-type invasive pneumococcal disease among children. [8] [9] [10] To measure progress towards reducing the burden of pneumococcal and Hib disease and inform the introduction and sustained use of prevention and treatment policies in the era of conjugate vaccines, we prepared annual modelled country-specific estimates of pneumococcal and Hib morbidity and mortality from 2000 to 2015 in children aged 1-59 months using countryspecific data inputs whenever possible.
Methods

Conceptual models and inputs
We estimated annual pneumococcal and Hib deaths, cases, mortality rates, and incidence rates for each country from 2000 to 2015 for each of the three primary syndromes associated with these pathogens: pneumonia, meningitis, and invasive non-pneumonia, nonmeningitis (NPNM). We developed conceptual models for each syndrome (figure 1). For the pneumonia models, we identified PCV and Hib vaccine trials and effectiveness studies from a systematic review of the literature (see appendix pp 4-8 for search strategy) and a Cochrane review of PCV efficacy. 11 We also updated a systematic review 12 of pneumococcal and Hib invasive disease from 1980 to 2005 with published and unpublished data up to and including 2014 for the pathogen-specific meningitis and NPNM models. We searched six global databases (ie, PubMed, Embase, Biosis, Cochrane, Global Health, and Pascal) and five regional databases (ie, IMEMR, IMSEAR, LILACS, WHOLIS, and WPRIM) and followed the same quality assessment criteria described in the previously published literature review. 12 We also used unpublished data from the Hib Rapid Assessment Tool and WHO Invasive Bacterial Disease surveillance network. 13 Other model parameter values were obtained from publicly available sources or personal communication. We used state-specific input values for India whenever possible and developed subnational models to account for wide disparities across states in the country.
An independent expert committee and the Immunization and Vaccines Related Implementation Research Advisory Committee at WHO reviewed the conceptual models and inputs (appendix pp [33] [34] . A country consultation was undertaken by WHO to verify with country representatives the method ology and country-specific model inputs. Where evidence was unavailable or contradictory, we selected the most conservative approach that would be likely to under estimate disease. Our rationale was to
Research in context
Evidence before this study We previously conducted a systematic review of invasive disease caused by Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib). On the basis of this review and using data from other sources, pneumococcus was estimated to be responsible for 735 000 deaths and Hib for 363 000 deaths in HIV-uninfected children in 2000. Updated estimates later published online for the year 2008 estimated that pneumococcus accounted for 541 000 deaths and Hib accounted for 203 000 deaths that year. The Institute for Health Metrics and Evaluation estimated that pneumococcus was responsible for 393 000 pneumonia deaths and Hib for 59 000 pneumonia deaths in children younger than 5 years in 2015.
Added value of this study
We present updated national estimates of pneumococcal and Hib mortality and morbidity due to all syndromes associated with these pathogens (ie, pneumonia, meningitis, and other invasive diseases) from 2000 to 2015. These estimates incorporate new data from 67 studies published between 2006 and 2014 that report on pathogen-specific meningitis case fatality and the distribution of meningitis cases by aetiology. Methods for estimating pneumococcal and Hib meningitis morbidity and mortality have been updated. To account for substantial within-country disease risk disparities, we developed India subnational pathogen-specific disease burden models for all syndromes associated with these pathogens for the first time.
Implications of all the available evidence To our knowledge, the results presented here are the most up-to-date estimates available of pneumococcal and Hib mortality and morbidity attributable to all syndromes. These estimates highlight global progress towards reducing the morbidity and mortality associated with these two pathogens and indicate countries and regions where intensified prevention and treatment efforts are needed. They can be used to inform national child health intervention strategies.
See Online for appendix minimise the likelihood that policy decisions would use overestimated burden estimates.
We report modelled pathogen-specific cases and deaths for each syndrome. Country-level results are available in the appendix (pp 36-145). Aetiology-specific deaths and cases, including country-specific estimates presented in the appendix, are modelled and not based on direct national reporting. We used world population estimates to calculate mortality and incidence rates reported as cases or deaths per 100 000 children aged 1-59 months. Population numbers were obtained from the United Nations Population Division. 14 Global and regional results are the sum of country-specific estimates. Results for deaths and cases were rounded and reported with three significant digits or fewer; precision was not provided for fewer than 100 cases or deaths. Incidence and mortality rates were rounded to the nearest integer.
All analyses were done using Stata 14 (College Station, TX, USA). This analysis is compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (appendix p 35).
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Pathogen-specific pneumonia
To estimate aetiology-specific pneumonia deaths and cases, we applied aetiological fractions to annual, country-specific all-cause pneumonia deaths and cases prepared by WHO and the Maternal and Child Epidemiology Estimation (MCEE) collaboration ( figure 1A) . 16 All-cause pneumonia estimates published by the WHO/MCEE collaboration already take into account immunisation with PCV and Hib vaccine. To avoid overestimating the vaccine effect, we adjusted allcause pneumonia deaths and cases to represent the burden of pneumonia that would have occurred had PCV and the Hib vaccine not been introduced. We assumed Hib pneumonia deaths and cases occurred only in children aged 1-23 months as described in the appendix (p 30). Pathogen-specific pneumonia, meningitis, and NPNM morbidity and mortality conceptual models MCEE=Maternal and Child Epidemiology Estimation. NPNM=non-pneumonia, non-meningitis. CFR=case-fatality ratio. *See Methods for description of vaccine adjustments. †Pneumococcal NPNM cases are stratified by severe and non-severe cases. ‡We assumed non-severe pneumococcal NPNM cases to have a 0% CFR; all pneumococcal NPNM deaths are assumed to be severe. 
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We determined the proportion of all-cause pneumonia mortality and morbidity attributable to pneumococcus and Hib using the probe approach we previously developed and described.
1,2 Briefly, we meta-analysed efficacy and effectiveness results from six PCV and four Hib vaccine randomised controlled trials and casecontrol studies with random or systematic allocation of treatment with PCV [17] [18] [19] [20] [21] [22] [23] [24] [25] and Hib vaccine [26] [27] [28] [29] [30] and allcause pneumonia case definitions. [31] [32] [33] Because vaccine trials and studies did not assess efficacy against pneumonia mortality, we used values of efficacy and effectiveness against radiography-confirmed, primary endpoint pneu monia (ie, consolidation), 33 with relevant adjustments, to approx imate the proportion of pneumonia deaths caused by each pathogen. We used values of PCV and Hib vaccine efficacy and effectiveness against WHO-defined clinical and severe pneumonia 30, 32 to estimate the contributions of each pathogen to these case definitions. Efficacy and effectiveness values were adjusted to account for incomplete efficacy against vaccine-type pneumonia. Because true efficacy values for vaccine-type pneumonia in children are not known, we used the observed efficacy against vaccine-type invasive disease for each trial as a proxy. For pneumococcus, we estimated the degree of bias this proxy measure introduced by using two sensitivity analyses described in detail in the appendix (pp 27-29): (1) vaccine-type acute otitis media (AOM) efficacy and (2) the ratio of the vaccine efficacy against vaccine-type invasive pneumococcal disease to that of vaccine-type non-bacteraemic pneumo coccal pneumonia detected by a novel serotype-specific urinary antigen assay in a PCV trial 34 done in Dutch adults older than 65 years. PCV efficacy values were also adjusted by the proportion of disease that was vaccine-type using invasive pneumococcal disease serotype distribution in the control group and by the proportion of pneumonia cases caused by Hib, because all PCV trials were done in the context of Hib vaccine.
Pathogen-specific meningitis
The conceptual model used to estimate pathogen-specific meningitis deaths was the same as for pathogen-specific pneumonia deaths (figure 1B). To calculate pathogenspecific meningitis cases, we divided pathogen-specific meningitis deaths by country-specific and pathogenspecific meningitis case-fatality ratio (CFR) estimates.
No studies were identified that reported the distribution of meningitis deaths by pathogen. We therefore used studies reporting the distribution of meningitis cases and adjusted these estimates by the relative pathogen-specific meningitis CFR to calculate the proportion of meningitis deaths due to pneumococcus and Hib, as described in the appendix (p 31). To estimate the proportion of meningitis cases due to each pathogen, we used data from observational studies because the aetiological diagnostic yield from investigations of meningitis cases is high when done with appropriate clinical and microbiological methods. Data from 98 studies reporting aetiologically confirmed bacterial meningitis cases attributable to common causes of bacterial meningitis were combined in random effects meta-analyses stratified by region.
We estimated pathogen-specific meningitis CFR using data from the systematic literature review (53 estimates for pneumococcus and 61 estimates for Hib), stratified by child mortality setting as previously defined: low (<30 deaths per 1000 livebirths), medium (30 to <75 deaths), high (75 to <150 deaths), and very high (≥150 deaths). 1, 2 Because reported CFR values reflect mortality in children who access care at a study site or health facility, we adjusted CFR values to account for the higher CFR (ie, 90% for all pathogens, as recommended by the independent expert committee) assumed for those who did not access care. There is no measure of care-seeking for children with meningitis in standardised surveys; therefore, we used the proportion of children seeking care for pneumonia symptoms from Multiple Indicator Cluster Surveys and Demographic and Health Surveys as a proxy. We assumed 100% access to care in countries with low child mortality. We assumed a linear relationship between access to care over time to estimate for years missing data. In the three countries without access-tocare data or the 24 countries with only 1 year of access-tocare data from these datasets, we developed a generalised linear model to explain the relationship between child mortality and access to care so that we could extrapolate from countries with access-to-care data.
Pathogen-specific invasive NPNM
Pathogen-specific cases due to other invasive syndromes (eg, sepsis) were estimated using random effects metaanalyses of the ratio of pathogen-specific NPNM cases to pathogen-specific meningitis cases reported from 46 studies for pneumococcus and 28 studies for Hib studies ( figure 1C ). Analyses were stratified by child mortality setting and, for pneumococcus, by severe and non-severe cases. We estimated NPNM deaths by multiplying NPNM cases by NPNM CFR. The latter was derived for each pathogen by estimating the ratio of NPNM CFR to meningitis CFR by child mortality setting and applying the ratio to meningitis CFR estimates.
HIV prevalence
Children infected with HIV who die from any cause, including pneumococcus or Hib, are accounted for in HIV death estimates. 16 We therefore estimated pneumococcal and Hib deaths for each syndrome in HIV-infected children using annual estimates of HIV prevalence in children younger than 59 months of age provided by UNAIDS (personal communication with BW) and estimates of relative risk for invasive pneumococcal disease and invasive Hib disease in HIV-infected children from the supplemental material for previously published estimates.
1,2 We assumed children on highly active antiretroviral therapy (HAART) had the same risk of pneumococcal and Hib disease as did HIV-uninfected children. UNAIDS and the US President's Emergency Plan for AIDS Relief provided the number of children on HAART therapy for 35 countries in 2015 (personal communication with BW). We assumed no HAART coverage in other countries.
Immunisation
We accounted for vaccine impact by subtracting the number of deaths and cases in children estimated to have been directly and indirectly protected by vaccination from the total number of pathogen-specific deaths and cases. Country-specific WHO and UNICEF Hib vaccine coverage estimates 35 were adjusted to represent the annual proportion of children aged 1-23 months at risk of disease on the basis of the number of years after vaccine introduction and assuming no catch-up campaigns. For PCV, we stratified pneumococcal disease estimates by age on the basis of a review of its age distribution 36 and applied vaccine coverage for each birth cohort to the corresponding estimate of pneumococcal disease for that age. Vaccine coverage estimates were combined with vaccine efficacy estimates and, in the case of PCV, regional estimates of disease serotype coverage by vaccine formulation prior to vaccine introduction 4, 37 to estimate the proportion of children directly protected by vaccination. We used vaccine-type invasive pneumococcal disease efficacy and serotype coverage as proxies for vaccine-type pneumococcal pneumonia efficacy and the distribution of serotypes causing pneumococcal pneumonia, respectively. 11, 37 To estimate the herd protection associated with Hib vaccine in children, we used data from vaccine studies measuring the impact of Hib vaccine on invasive Hib disease and modelled the proportion of children protected on the basis of WHO and UNICEF coverage estimates using the same methods previously reported with updated model inputs.
1,2 Although we were unable to make assumptions about herd immunity in the years following the introduction of PCV in the same way owing to too few datapoints, we assumed 95% of children were protected from vaccine-type pneumococcal disease 5 years or more after the introduction of PCV if reported vaccine coverage exceeded 65%. 38 We also accounted for an increase in disease caused by nonvaccine serotypes in countries where the seven-valent PCV product (PCV7) was used (ie, serotype replacement). For this, we used data from a systematic review 38 reporting the relative risk for non-vaccine-type invasive pneumococcal disease each year following the introduction of PCV7. Because serotype replacement in invasive pneumococcal disease might underestimate the extent of replacement observed for pneumococcal pneumonia, we did a sensitivity analysis assuming full replacement by non-PCV7 serotypes for pneumococcal pneumonia. Summary estimates are not yet available for higher valency PCV products and so we did not account for serotype replacement when and where these vaccines were used. HIV infected 1300 (500-2700) 1100 (400-2300) <100 <100 <100 100 (100-300)
<100
Data are estimates (uncertainty range). Mortality and incidence rates are per 100 000 children. Morbidity estimates (ie, incidence rates and cases) include children regardless of HIV infection. Mortality estimates (ie, mortality rates, deaths, and CFR) do not include HIV-infected children except where specified. CFR=case-fatality ratio. Pneumococcus=Streptococcus pneumoniae. NPNM=non-pneumonia, non-meningitis. *Derived from UN World Population Prospect 2015. †Data from UN Interagency Group for Child Mortality Estimation 2015. ‡From Maternal and Child Epidemiology Estimation/WHO collaboration estimates. 14 §Severe NPNM only. 
Uncertainty
We estimated the uncertainty around our estimates using methods similar to previous analyses.
1,2
For pathogen-specific pneumonia estimates, uncertainty intervals were based on a jack-knife, leave-one-study-out approach for the upper and lower bounds of the pneumococcal and Hib pneumonia fractions. For meningitis aetiology estimates, we determined the most conservative (ie, wide) uncertainty estimates for aetiological proportions on the basis of a jack-knife leaveone-study-out analysis and reported confidence intervals from meta-analyses. Pathogen-specific NPNM morbidity and mortality uncertainty ranges were based on uncertainty from pathogen-specific meningitis models. We did not account for uncertainty in other model parameter values (ie, vaccine coverage or access to care) or all-cause mortality estimates.
Role of the funding source
The sponsor of this study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit this report for publication. All authors had full access to all the data used in the study and the corresponding author had final responsibility for the decision to submit for publication.
Results
We estimated that pneumococcus was responsible for 294 000 deaths (uncertainty range By the end of 2015, 129 countries were using PCV. Pneumococcal deaths declined most sharply between 2010 and 2015, when the average annual reduction was 8%, compared with just 3% from 2000 to 2010. After 2010, 52 Gavi-eligible countries-many of them countries with the highest pneumococcal disease burden-introduced PCV in their national immunisation programmes. We estimated that PCV prevented 250 000 cumulative pneumococcal-related deaths from 2000 to 2015, with more than 95% of them prevented after 2010. A sensitivity analysis suggests that our adjustment for serotype replacement for PCV7 could overestimate averted deaths by 3100 deaths. Nevertheless, total pneumococcal deaths among HIV-uninfected children aged 1-59 months remained substantial in 2015, accounting for at least 11% (UR 7-13) of all mortality in that age group.
The updated proportion of radiography-confirmed pneumonia attributable to pneumococcus before accounting for vaccination, which included data from two additional studies, 24, 25 was estimated to be 34% (UR 24-36). Our sensitivity analysis using vaccine-type efficacy of AOM found the proportion could be as high as 51% . This assumes that the efficacy of PCV against vaccine-type pneumococcal pneumonia is as low as the efficacy of PCV against vaccine-type pneumococcal AOM. Furthermore, our second sensitivity analysis showed the proportion of radiography-confirmed pneumonia caused by pneumococcus could be as high as 65% if the ratio of PCV efficacy against vaccine-type pneumococcal pneumonia to that of vaccine-type invasive pneumococcal disease in children is similar to that observed among the Dutch elderly population. 34 We provide country-specific pneumococcal pneumonia mortality estimates using these sensitivity parameters in the appendix (pp 146-174).
India (68 700 deaths, UR 44 600-86 100), Nigeria (49 000 deaths, 32 400-59 000), the Democratic Republic of , and Angola (216, 148-248) had the highest pneumococcal mortality rates per 100 000 children aged 1-59 months. We estimated 8·9 million cases (UR 7·7 million-10·6 million) of clinical pneumococcal pneumonia, irrespective of HIV status, in 2015-a reduction of 37% from 14·2 million cases (12·3 million-16·9 million) in 2000. We also estimated 3·5 million cases (2·6 million-4·0 million) of severe pneumococcal pneumonia in 2015, a reduction from 5·6 million cases (4·2 million-6·4 million) in 2000. We also estimated 83 900 cases (36 100-169 000) of pneumococcal meningitis in 2015 in children regardless of HIV status, providing a global incidence rate of 13 cases (5-26) per 100 000 children aged 1-59 months. Pneumococcal meningitis cases and deaths estimated for 2000 using our updated models were very similar to the previously published estimates. 1 Pneumococcal NPNM contributed 326 000 cases (142 000-653 000) in 2015, of which 22% were severe (table 1) .
With regard to Hib, we estimated that there were 29 500 (UR 18 400-40 700) Hib deaths in HIV-uninfected children aged 1-59 months in 2015, all of which we estimated to have occurred in children aged 1-23 months. Hib was estimated to contribute to fewer than 1000 additional deaths in children infected with HIV (table 2) . Of Hib deaths in HIV-uninfected children in 2015, 76% were due to pneumonia, 24% to meningitis, and less than 1% to NPNM (table 2). Hib deaths declined by 90% (78-96) from 2000, when there were an estimated 299 000 deaths (186 000-412 000) in HIVuninfected children (figure 2). The substantial decrease in Hib mortality corresponded with an increase in the number of countries using Hib vaccine between 2000 (n=60) and 2015 (n=192). We estimated that Hib vaccine prevented approximately 1·2 million total deaths from 2000 to 2015, not including the Hib deaths prevented in HIV-infected children.
Approximately 82% of all Hib deaths in HIV-uninfected children in 2015 (24 200 deaths, UR 15 000-33 400) occurred in the Africa and southeast Asia regions (figure 4), which together accounted for 51% of the child population in that year. The greatest reductions in Hib deaths from 2000 to 2015 were observed in the eastern Mediterranean (97%) and in the Americas (96%; appendix pp 72-107). The countries with the greatest number of total Hib deaths (excluding those in HIVinfected children) in 2015 were India (15 600 deaths, 9800-21 500), Nigeria (3600 deaths, 2200-5100), China (3400 deaths, 2300-4600), and South Sudan (1000 deaths, 600-1400). The highest estimated Hib mortality rates per 100 000 children aged 1-59 months in 2015 were in South Sudan (54, UR 33-75), Equatorial Guinea (43, , and Somalia (26, 14-37) (figure 4).
There were 0·9 million estimated cases (UR 0·9 million-1·5 million) of clinical Hib pneumonia in 2015, irrespective of HIV status. Of these, 298 000 cases (179 000-602 000) were estimated to also be severe pneumonia. Assuming all Hib pneumonia deaths were among severe cases, the global inferred CFR was 8% (5-10) in 2015 for children not infected with HIV. We estimated 31 400 cases (13 400-50 800) of Hib meningitis 
Discussion
To our knowledge, we present the first comprehensive (ie, pneumonia, meningitis, and NPNM) country-level HIV infected <100 <100 <100 <100 <100 <100 <100 (Table 2 continues on next page) estimates of pneumococcal and Hib disease burden since the estimates 1,2 for the year 2000 published in 2009, as well as the first comprehensive regional and global burden estimates for these pathogens since they were updated for 2008. 3 We estimated that pneumococcal and Hib deaths in children declined substantially in the era of conjugate vaccines.
Most pneumococcal and Hib deaths in 2015 were limited to a few countries in Africa and Asia. We estimated that four countries (India, Nigeria, China, and South Sudan) had more than 1000 Hib deaths in 2015. India and Nigeria introduced the Hib vaccine in 2011 and 2012, respectively; however, estimated national coverage in both countries was relatively low (ie, <50%) thereafter. South Sudan introduced the Hib vaccine in 2014. Hib deaths in these countries will probably decline as Hib vaccine coverage increases. China remained one of three countries that had not introduced Hib vaccine by 2015, along with Thailand and Russia. Likewise, half of global pneumococcal deaths in 2015 were limited to only four countries in Africa and Asia (India, Nigeria, the Democratic Republic of the Congo, and Pakistan). Pakistan and the Democratic Republic of the Congo introduced PCV in 2012. Nigeria began routine immunisation with PCV in 2014 and India started routine use in three states in 2017. Progress towards prevention of pneumococcal deaths in these countries will accelerate the global reduction in pneumococcal deaths.
The syndromic distribution of pneumococcal and Hib deaths was dominated by pneumonia, underscoring that disease burden estimates for these pathogens are highly sensitive to changes in all-cause pneumonia deaths, which are an independent input value in our pathogen-specific models. Given the low sensitivity of diagnostic tests for determining bacterial causes of pneumonia, we continued to use the probe approach to determine the fraction of 
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HIV uninfected <100 <100 <100 <100 <100 <100 <100
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Data are estimates (uncertainty range). Mortality and incidence rates are per 100 000 children. Morbidity estimates (ie, incidence rates and cases) include children regardless of HIV infection. Mortality estimates (ie, mortality rates, deaths, and CFR) include only HIV-infected children unless specified. CFR=case-fatality ratio. Our updated estimate of radiography-confirmed pneumonia cases attributable to pneumo coccus is similar to values estimated in previous models. Using this value as a proxy for the proportion of pneumonia deaths attributable to each pathogen inherently implies that the pneumonia CFR for radiography-confirmed pneumococcal pneumonia is equivalent to the CFR for radiography-confirmed Hib pneumonia, and that they are equal to the CFR for other causes of radiography-confirmed pneumonia. Globally, most (81%) pneumonia deaths are estimated to occur in the community, 39 presumably with poor access to effective antibiotics. In such settings, the CFR of bacterial pneumonia is likely to be substantially higher than for non-bacterial pneumonia, revealing that our proxy method contributes to underestimating pneumococcal and Hib pneumonia deaths in settings of low access to care-the same settings that account for the greatest burden of pneumonia deaths.
We used vaccine-type invasive pneumococcal disease efficacy as a proxy for vaccine-type pneumococcal pneumonia efficacy when determining the proportion of pneumonia deaths caused by pneumococcus in the probe approach. This choice probably leads to an underestimate of the contribution of pneumococcus to pneumonia deaths and so we considered several alternatives. Based on the sensitivity analysis using vaccine-type AOM efficacy as the proxy value for vaccine-type pneumococcal pneumonia efficacy, pneumococcal pneumonia deaths could be as much as 51% higher than estimated by the base-case model. However, these results should be approached with caution as the efficacy against vaccine-type AOM is not likely to reflect the efficacy against vaccine-type pneumococcal pneumonia. Using vaccine-type nonbacteraemic pneumococcal pneumonia efficacy in an elderly Dutch population 34 as the relative proxy, the estimate of pneumococcal pneumonia deaths in children is twice that estimated by our base-case model. This method assumes the relative vaccine efficacy against bacteraemic and non-bacteraemic pneumococcal pneumonia in elderly people reflects the same ratio in children. However, there is little evidence to support this assertion. Furthermore, if the urine antigen test used to identify the non-bacteraemic pneumococcal pneumonia cases in the Dutch trial also detects antigenuria on the basis of vaccine-type pneumococcal nasopharyngeal colonisation, the observed efficacy value in that trial could reflect a contribution of vaccine efficacy against nasopharyngeal colonisation with vaccine-type pneumococcus, which would probably be lower than the true vaccine-type pneumococcal pneumonia efficacy est imate. 34 The limitations associated with these sensitivity analyses contributed to our decision to use vaccine-type invasive pneumococcal disease efficacy in the base-case model.
Until highly specific diagnostic approaches for vaccinetype non-bacteraemic pneumococcal pneumonia in children are available, the validity of these sensitivity analyses will remain unclear. Nevertheless, they do emphasise that our base-case estimates are very likely to be underestimates, possibly by as much as 100%. Our decision around which base-case analysis to use was also informed by consultation with external experts and a review of PCV impact studies with clinical pneumonia outcomes in several high-income and middle-income settings (appendix pp [22] [23] . Where parameter selection could not be grounded in clear evidence, we erred on the side of being conservative in our approach (ie, making decisions that would lead to an underestimate of disease burden). As evidence continues to accrue, we will revisit the assumptions in the base-case model. We have provided the results of the country-level pneumo coccal pneumonia estimates using the sensitivity analyses in the appendix (pp 146-74) to provide full access to the range of possible disease burden estimates for each country. Recently reported pneumo coccal pneumonia disease burden estimates for 2015 from the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease collaboration use the vaccine-type pneumococcal pneumonia efficacy value in elderly people in their basecase model. 40 Consequently, pneumococcal pneumonia deaths estimated by the IHME-approximately 393 000 in children aged 1-59 months-are greater in number than those presented here.
We prepared annual estimates of pneumococcal and Hib disease burden from 2000 to 2015, allowing us to make comparisons with previously published estimates. We previously estimated 735 000 pneumococcal deaths 1 and 363 000 Hib deaths in 2000 in HIV-uninfected children. 2 By comparison, we estimated 600 000 pneumo coccal deaths and 299 000 Hib deaths in 2000 excluding HIVinfected children, using updated methods and new data. We observed similar differences comparing the current mortality estimates with those for the year 2008, 3 which were generated using the original model with updated input values. Pathogen-specific URs for disease burden estimates for the years 2000 and 2008 from current and previously published methods overlap substantially. In addition, our validation for pneumo coccal disease (appendix p 177) suggests that our pneumococcal disease burden estimates are likely to be underestimated but within the confidence bounds. We were unable to validate the plausibility of our Hib cases and deaths because we found no other study that independently quantified the burden accounting for the poor diagnostic sensitivity.
All-cause child mortality has been decreasing in almost all low-income and middle-income countries as a result of vaccine and non-vaccine interventions. 41, 42 As this trend continues, morbidity associated with childhood illnesses, which is less affected by non-vaccine interventions, will play an increasingly important role in programme planning and policy making. We prepared countryspecific estimates of severe and non-severe disease associated with pneumococcus and Hib, which can be used for these purposes.
The availability of all-cause meningitis death estimates allowed us to shift from an incidence-based model to a proportion-based model. The motivation for this shift was to ensure that any pathogen-specific meningitis mortality estimates were inherently bounded by the total meningitis mortality. The sum of pathogen-specific death estimates derived using incidence data could theoretically exceed the total number of meningitis deaths. In addition, if the sensitivity of meningitis diagnostic tests is reasonably similar for each pathogen, using a relative distribution of pathogens (ie, our proportion-based method) could be less likely to underestimate the pathogen-specific burden of meningitis. We were unable to account for outbreaks of pneumococcal meningitis, which could lead to an underestimate of meningitis disease burden, particularly countries in sub-Saharan Africa. To provide context to aetiology-specific meningitis death and case estimates derived using the proportion-based method, we also estimated pneumococcal and Hib meningitis mortality and morbidity using the incidence-based model (appendix pp 175-76).
Our pathogen-specific meningitis and NPNM models rely on data from a systematic literature review of studies published between 1990 and 2014. For the proportionbased approach, we used studies that were conducted prior to the introduction of any conjugate vaccine. As most countries (n=192) were using Hib vaccine at the end of 2015, we anticipated very few additional studies would contribute data. Methods that do not rely on data from the era prior to the introduction of Hib vaccine will be needed to assess the burden of pneumococcal and Hib disease in the future.
Our model may have overestimated the impact of vaccination in children, particularly for PCV, due to the limited availability of data. We use country-specific vaccine coverage data from WHO and UNICEF. Reported coverage data have been observed to underestimate and overestimate coverage. The latter is more likely to occur when estimates are based on administrative data. 43 As a result, our model could have overestimated the impact of vaccination. National vaccine coverage estimates can also mask regional and local coverage disparities. If those at risk of disease, independently of whether they received vaccine, are differentially reached by vaccination programmes, our model will overestimate the effect of immunisation. We also assumed serotype replacement for pneumococcal pneumonia to occur with the same frequency as invasive pneumococcal disease. We were also unable to account for serotype replacement in countries where PCV10 or PCV13 were routinely used. We probably overestimated vaccine impact in both cases. However, the extent to which vaccine impact is overestimated in any of these cases remains unknown. It is important to note that PCV and Hib vaccine probably provide protection to other age groups not included in this analysis.
These estimates should not be interpreted as a primary source of vaccine impact data and cannot be used to validate vaccine impact measured directly in the field as our models rely on assumptions of vaccine efficacy and effectiveness to estimate vaccine impact. However, our results can be used to emphasise the efforts of several organisations working to expand access to these vaccines. Our modelled estimates suggest an accelerated reduction in pneumococcal burden in the years after 2010 when the Advanced Market Commitment for PCV, a financing mechanism for the development of new vaccines, was launched by Gavi. 44 The availability of funding for PCV in low-income and middle-income countries with the highest disease burden accelerated its adoption and therefore the reduction in pneumococcal deaths.
Pathogen-specific pneumonia and meningitis deaths are constrained by the all-cause pneumonia and meningitis death estimates produced by the WHO/ MCEE collaboration. 16 Given that few deaths occur in countries with adequate vital registration systems, these estimates are based largely on verbal autopsy data. The potential for misclassification and other challenges associated with verbal autopsy studies, particularly for non-specific syndromes such as pneumonia, have been described extensively. 45, 46 Given the dependence of the present pathogen-specific mortality estimates on allcause pneumonia and meningitis deaths, advances in improving the confidence of cause of death estimates in high child-mortality settings would also positively affect pathogen-specific estimates.
Although we accounted for the increased risk of pneumococcal and Hib disease in children infected with HIV, we only accounted for the use of HAART among HIV-infected children in 35 countries in 2015. Studies have shown a marked reduction in pneumococcal disease in children younger than 18 years after the widespread use of HAART. 47 Failing to account for HAART use in all countries probably leads to an overestimate of the pneumococcal and Hib disease burden in HIV-infected children. In addition, we were unable to account for HIVexposed but uninfected children who are at increased risk of morbidity and mortality from invasive pneumo coccal disease. 48 Other than HIV, we were unable to account for other underlying risk factors for invasive bacterial diseases, including malaria infection 49 and sickle cell anaemia. 50 We assumed 0% Hib vaccine coverage for China: the vaccine is not used in the national immunisation programme; however, relatively high immunisation coverage through the private sector has been reported in some cities. 51, 52 We could not locate a reliable source of Hib vaccine coverage for the country. Although this would lead to an overestimate of disease, we believe those who would have access to the vaccine through the private sector would be at lower overall risk of disease compared with those without access to the vaccine. Despite these limitations, we believe the net effect of our estimates remains an underestimate of disease burden.
The burden of Hib disease is largely limited to a handful of countries that have not or only recently initiated routine use of Hib vaccine. Pneumococcal disease is beginning to decline substantially around the world, but still causes a large number of deaths and cases. The remaining burden of disease associated with these two pathogens warrants sustained and intensified efforts, including the introduction of vaccine in countries that have not yet introduced the vaccine and dedicated efforts to enhance coverage, particularly among children whose socioeconomic situation puts them at increased risk of disease.
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